

## Info Sheet for Technical description

No. XXXX (事務局付番)

### Organization

\* Mandatoty fields

Name of Organization*	REPROCELL Inc.	
Address, City, States, Zip, Country*	MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan	
URL	<a href="https://www.reprocell.com/">https://www.reprocell.com/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	1) Research Support Business Manufacture and sale of reagents for iPS cell research Provision of drug discovery support services (i.e., establishment of iPS cell lines, CRO services, etc.) Provision of biological samples Provision of genetic analysis services	
Contact address	Name*	
	Department* / Position	
	E-mail* / TEL	

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by\*

Date\*

Mitsuru Inamura
09/22/2023

**Sheet [B]** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. XXXX (事務局付番)

\* Mandatoty fields

**Title\*****Stem Cell Services for Cell Therapy Manufacturing****Category\***

- |  |  |   |
|--|--|---|
| <input checked="" type="checkbox"/> Facilities                                   | <input type="checkbox"/> Manufacturing equipment | <input type="checkbox"/> Inspection equipment |
| <input checked="" type="checkbox"/> Cells  | <input type="checkbox"/> Culture medium          | <input type="checkbox"/> Reagents             |
| <input checked="" type="checkbox"/> Cell banking                                 | <input type="checkbox"/> Storage / Container     | <input type="checkbox"/> Logistics            |
| <input checked="" type="checkbox"/> Cell / Viral vector manufacturing technology |  |   |

**Description\***

The GMP iPSC Master Cell Banks and cells that REPROCELL's scientists can manufacture for your cell therapy project that will be compliant with the regulatory standards and guidelines of the FDA, EMA, and PMDA. Our iPSC experts will provide the necessary quality and regulatory documents such as COA, batch records, and quality technical agreement for your GMP iPSC Master Cell Bank.

With global access to human tissue samples, we can procure the tissues needed for your cell therapy project and perform the necessary viral and donor profile screenings. Our experts use our proprietary footprint-free RNA reprogramming technology to generate a StemRNA™ Clinical iPSC Seed Clone Bank using GMP-grade media and reagents.

Under strict quality control measures, a clinical grade iPSC seed clone can be expanded in a GMP environment to manufacture a Master Cell Bank which can be further downstream processed to generate a therapeutic cell product.

REPROCELL's process starts with collecting skin for fibroblast isolation from screened donors who gave consent for clinical and commercial use, further reprogramming the fibroblasts to iPSCs using our proprietary StemRNA™ 4th Gen Technology. Multiple iPSC clones are isolated and quality controlled to create StemRNA Clinical iPSC Seed Clones, which are suitable for expansion into a GMP iPSC Master Cell Bank.

**Filled in by\***

Mitsuru Inamura

**Date\***

09/22/2023

**Sheet [B]** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. XXXX (事務局付番)

\* Mandatoty fields

**Title\*****Stem Cell Services for Cell Therapy Manufacturing****Category\***

- |  |  |   |
|--|--|---|
| <input checked="" type="checkbox"/> Facilities                                   | <input type="checkbox"/> Manufacturing equipment | <input type="checkbox"/> Inspection equipment |
| <input checked="" type="checkbox"/> Cells  | <input type="checkbox"/> Culture medium          | <input type="checkbox"/> Reagents             |
| <input checked="" type="checkbox"/> Cell banking                                 | <input type="checkbox"/> Storage / Container     | <input type="checkbox"/> Logistics            |
| <input checked="" type="checkbox"/> Cell / Viral vector manufacturing technology |  |   |

**Description\***

Thanks to the discovery of CRISPR-Cas9, gene editing is more accessible than ever before. However, some genetic modifications remain challenging and there are even more factors to consider if your cells are intended for clinical use. By outsourcing your clinical gene editing to REPROCELL, you can achieve the genotype you need before moving on to expensive cell bank manufacturing processes.

Our StemEdit service uses advanced CRISPR-SNIPER\* gene editing technology to develop your engineered stem cells. Due to the increased screening specificity of CRISPR-SNIPER, we can successfully achieve complex genetic edits with high accuracy at an early stage. By evaluating the percentage of target cells and determining their transfection efficiency (go/no-go decision point) StemEdit saves time as the SNIPER pre-screen is performed before laborious clone selection.

**Filled in by\***

Mitsuru Inamura

**Date\***

09/22/2023